Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASE: rHDL in Acute Coronary Syndrome
NCT00225719Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Jul 2005
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CSL-111 in acute coronary syndrome (ACS) (3 arms), sponsored by CSL Limited. Primary endpoint: Percentage Atheroma Volume at 6 weeks. Started Jul 2005; status: completed.
02
Drugs
CSL-111
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00225719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225719.